PEPTONIC MEDICAL AB Inactive Instrument
Peptonic Medical AB Stock Nasdaq Stockholm
Equities
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - SEK | - |
|
| Jul. 03 | Peptonic Medical AB Granted Patent in Australia: Vernivia Secures Exclusivity Until 2038 | CI |
| May. 31 | Peptonic Medical Secures European Patent for Treatment of Vulvodynia | MT |
| Sales 2022 | 43.63M 4.16M | Sales 2023 | 37.12M 3.54M | Capitalization | 89.02M 8.49M |
|---|---|---|---|---|---|
| Net income 2022 | -36M -3.43M | Net income 2023 | -42M -4M | EV / Sales 2022 | 1.14 x |
| Net Debt 2022 | 15.77M 1.5M | Net cash position 2023 | 6.27M 597K | EV / Sales 2023 | 2.23 x |
| P/E ratio 2022 |
-0.92
x | P/E ratio 2023 |
-2.09
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 1.49% |
More Fundamentals
* Assessed data
More news
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Erik Sundquist
CEO | Chief Executive Officer | 54 | 21-04-13 |
Hadar Kessary
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Chief Operating Officer | 64 | 08-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Tarek Shoeb
BRD | Director/Board Member | 55 | 23-05-23 |
Karl Blom
BRD | Director/Board Member | 55 | - |
Anders Norling
BRD | Director/Board Member | 58 | 22-05-23 |
Peptonic Medical AB is a Sweden-based company active in the field of biotechnology. The Company develops estrogen-free pharmaceuticals for treatment of vaginal atrophy. The Company's main drug candidate is Vagitocin, an oxytocin-based pharmaceutical preparation for the treatment of vaginal atrophy and other menopause-related symptoms. The patented treatment is based on local, vaginal application of oxytocin to rejuvenate the vaginal mucosa. Vagitocin is to enter phase III clinical trials in Europe and the United States.
Calendar
2024-08-12
- Q2 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| +15.58% | 121B | |
| +16.60% | 110B | |
| +17.73% | 25.93B | |
| -24.33% | 19.27B | |
| -19.35% | 16.01B | |
| -17.95% | 15.66B | |
| -48.32% | 14.89B | |
| +58.78% | 14.47B | |
| +4.91% | 13.91B |
